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Introduction: Enhanced B cell activity, particularly memory B cells have gained interest in evaluating response
during therapies with biologics. CD27-IgD- double-negative (DN) B cells lacking the conventional memory marker
CD27 are reported to be part of the memory compartment, however, only scarce data is available for rheumatoid
arthritis (RA). We therefore focused on DN B cells in RA, studied their isotypes and modulation during interleukin-6
receptor (IL-6R) inhibition by tocilizumab (TCZ).
Methods: DN B cells were phenotypically analyzed from 40 RA patients during TCZ at baseline week 12, week
24 and 1 year. A single B cell polymerase chain reaction (PCR) approach was used to study Ig receptors, VH gene
rearrangements and specific isotypes.
Results: Phenotypic analysis showed a significantly expanded population of DN B cells in RA which contain a
heterogeneous mixture of IgG-, IgA- and IgM-expressing cells with a clear dominance of IgG+ cells. DN B cells
carry rearranged heavy chain gene sequences with a diversified mutational pattern consistent with memory B cells.
In contrast to tumor necrosis factor alpha (TNF-α) inhibition, a significant reduction in mutational frequency of BCR
gene rearrangements at week 12, 24 and 1 year (P <0.0001) was observed by in vivo IL-6R inhibition. These changes
were observed for all BCR isotypes IgG, IgA and IgM at week 12, 24 and 1 year (P <0.0001). IgA-RF, IgA serum level
and IgA+ DN B cells decreased significantly (P <0.05) at week 12 and week 24 during TCZ. Patients with a good
European League Against Rheumatism (EULAR) response to TCZ had less DN B cells at baseline as compared to
moderate responders (P = 0.006). Univariate logistic regression analysis revealed that the frequency of DN B cells at
baseline is inversely correlated to a subsequent good EULAR response (P = 0.024) with an odds ratio of 1.48 (95%
confidence interval as 1.05 to 2.06).
Conclusions: In RA, the heterogeneous DN B cell compartment is expanded and dominated by IgG isotype. TCZ
can modulate the mutational status of DN Ig isotype receptors over 1 year. Interestingly, the frequency of DN B
cells in RA may serve as a baseline predictor of subsequent EULAR response to TCZ.Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflam-
matory, autoimmune disease characterized by inflamma-
tion of the joints, which results in their progressive
destruction [1,2]. Recent studies suggest that B cells play
an important role in the development and progression of
RA through several mechanistic pathways, and the subse-
quent polyclonal activation of B cells [3]. By producing* Correspondence: Mahmood_Z@ukw.de; Tony_H@ukw.de
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stated.different inflammatory cytokines and autoantibodies, they
may directly drive pathologic inflammation [4]. Moreover,
memory B cells have gained particular interest in evaluat-
ing response during therapies from biologics that have
shown promising results in treatment of RA. Different
cytokines are involved in B cell differentiation, mainten-
ance and survival. They are distinctly implicated in each
phase of the pathogenesis of RA-promoting autoimmun-
ity, maintaining chronic inflammatory synovitis and driv-
ing the destruction of joint tissue [5]. Biological agents
targeting key proinflammatory cytokines, such as tumor
necrosis factor alpha (TNF-α) and interleukin 6 (IL-6)tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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autoimmunity [6]. IL-6 is a multifunctional pleiotropic
cytokine acting as stimulator of both B and T cell func-
tions. It is produced by various cells of the innate im-
mune system (for example macrophages, dendritic cells,
mast cells, neutrophils), B cells, and to some extent by
CD4 effector T helper (Th) cells [7]. IL-6 also influences
various cell types and has multiple biological activities
through its unique receptor system [8]. It has been
described as a late-acting B cell differentiation factor
that is involved in in vitro differentiation of B cells into
antibody-forming cells and germinal center reactions. In
addition to its involvement in immune responses, it also
regulates hematopoiesis, the acute phase response and
inflammation. Dysregulation of IL-6 production and its
pathological role in different autoimmune diseases have
been well documented and highlight IL-6 and its signaling
cascade as a potential target for autoimmune therapy
[9-13]. Consequently, tocilizumab (TCZ), a humanized
anti-IL-6 receptor (IL-6R) monoclonal antibody (mAb)
against the alpha chain of IL-6R, which prevents binding
of IL-6 to membrane and soluble IL-6R, was developedFigure 1 Phenotype analysis of CD27-IgD- B cells in RA patients and
Characterization of (CD27-IgD-) DN B cells, PS = post-switch (CD27 + IgD-), P
(B) Comparison of DN B cells in RA patients and HD. DN B cells in RA patie
of the frequency of DN B cells in RA patients (P <0.0001). (C) EULAR respon
5.1 ± 0.3) to TCZ have significantly (P = 0.006) lower frequency of DN B cells
5.3 ± 0.3). (D) EULAR responses to IL-6R inhibition (absolute cell numbers).
absolute DN B cell numbers at baseline compared to moderate responders
percentiles and the lines within the boxes represent the median. P values w
(***P <0.0001, **P <0.001 and *P <0.05). BL DAS28, baseline disease activity s
Rheumatism; HD, healthy donor; Ig, immunoglobulin; IL-6R, interleukin-6 reand has been licensed for the treatment of RA [14]. TCZ
has shown convincing clinical efficacy by reduction of
signs/symptoms and a marked inhibition of radiological
progression [11].
Functionally distinct B cell subsets can be defined by
the phenotype expression of CD27 and immunoglobulin
D (IgD). Human peripheral memory B cells are mainly
discriminated from naïve B cells by the phenotypic ex-
pression of CD27 (a member of the tumor necrosis
factor receptor (TNFR) family) and presence of somatic
hypermutation (SHM) in their Ig variable genes [15,16].
CD27 expression by B cells has been considered a hall-
mark for SHM and their memory. CD27+ memory B cells
are a heterogeneous population comprising of pre-switch
(IgD +CD27+) and post-switch (IgD-CD27+) B cell sub-
sets [13,17,18]. There are still unanswered questions about
the exact identification of memory B cells based on CD27
expression, since recent studies in these lines have shown
a double-negative (DN) population (CD19 + CD27-IgD-)
that bears all signatures of memory B cells [19-21]
(Figure 1A). A very large portion of DN (CD27-IgD-) B
cells express mutated Ig and an evaluation of telomeretheir relation to EULAR response. (A) Representative FACS plot.
re = pre-switch (CD27 + IgD+) and naïve (CD27-IgD+) B cells.
nts (n = 44) and HD (n = 45) show a significantly higher percentage
se to IL-6R inhibition. Week 12 EULAR good responders (BL DAS28 =
at baseline compared to EULAR moderate responders (BL DAS28 =
Week 12 EULAR good responders have significantly (P = 0.05) lower
. Data shown in box-whisker plot where boxes represent 25th to 75th
ere determined by Mann-Whitney U test using GraphPad Prism 5.
core 28; DN, double-negative; EULAR, European League Against
ceptor; RA, rheumatoid arthritis; TCZ, tocilizumab.
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and absence of the ATP-binding cassette B1 transporter
(ABCB1) have been used to discriminate them from
naïve CD27- B cells and relate them to the memory B
cell compartment [22,23]. Even though DN memory B
cells mainly express switched Ig isotypes, they have a
reduced rate of SHM compared to post-switch B cells.
This has been hypothesized to be due to either an im-
paired germinal center (GC) formation or resembling a
distinct lineage of memory B cells [23,24]. In systemic
lupus erythematosus (SLE), DN B cells are expanded
and could be linked to autoimmunity by analysis of the
specific autoantibodies including 9G4 expression [19].
So far, the nature of DN B cells has still not been fully
delineated in general as well as in autoimmune diseases.
Our previous studies of memory B cell subsets during
in vivo IL-6R inhibition indicated phenotypic and mo-
lecular changes in pre-and post-switch memory B cells
[13,14,25]. In RA, DN B cells have not been thoroughly
studied and there is scarce information in the literature.
Therefore, we initiated the current study to analyze the
DN B cell compartment in RA in more detail by pheno-
typic and molecular analyses of the different isotypic DN
B cell receptors, their immunoglobulin receptor (Ig-R)
mutational pattern and their modulation by in vivo IL-
6R and TNF-α inhibition.
Methods
Patients and healthy donors
Peripheral blood was taken from 44 rheumatoid arthritis
patients (RA) with a median age of 54 (range 33 to 79)
years and 49 healthy age-matched donors (HD) for B cell
phenotype and molecular analysis. All patients met the
American College of Rheumatology revised criteria for
RA [26]. The patients had median disease duration of 9
(range 2 to 33) years and 77% were female. Informed
consent was obtained from all patients according to the
protocol approved by the ethics committee of the
university hospital, Würzburg, Germany. Patients who
failed to respond to treatment with standard disease-
modifying antirheumatic drugs (DMARDs) including
methotrexate (MTX) were eligible and enrolled in the
study. A dose of 8 mg/kg TCZ was administered every
4 weeks as a 60-minute infusion in combination with
MTX. Alternatively, adalimumab (ADA) (40 mg every
2 weeks) in combination with MTX was given as control.
The clinical primary end point was set at 12 weeks, with
an extension period up to 24 weeks and follow-up till
1 year. Forty TCZ-treated patients were followed at base-
line, weeks 12 and 24 for phenotypic analysis. A total of
33/40 patients were rheumatoid factor (RF)-positive and
28/40 patients were anti-citrullinated protein antibodies
(ACPA)-positive. Furthermore, all the ACPA-positive pa-
tients were positive for RF, 5/40 ACPA-negative patientswere RF-positive and 7/40 patients were negative for both
RF and ACPA. Four patients left the study after week 12.
For correlation with clinical parameters, 36 patients
undergoing TCZ therapy were studied, 14/36 reached a
European League Against Rheumatism (EULAR) good
response at week 12, 20/36 were EULAR moderate
responders and 2/36 were non-responders to TCZ. The
baseline disease activity score using 28 joint counts
(DAS28) and C-reactive protein (CRP) levels of EULAR
good responders (5.1 ± 0.3; 0.9 ± 0.2 mg/dl) and moder-
ate responders (5.3 ± 0.3; 0.8 ± 0.2 mg/dl), respectively
were similar [27]. Clinical characteristics of the patients
undergoing TCZ therapy are summarized in Table 1.
Nine RA patients under TCZ therapy, four patients under
anti-TNF-α therapy and three HD were selected for ana-
lysis of mutational patterns of Ig-Rs by single-cell poly-
merase chain reaction (PCR) technique.
Flow cytometric analysis
Whole blood staining was used for phenotype studies and
peripheral blood mononuclear cells (PBMCs) were used for
single-cell PCR approach. Whole blood and PBMCs were
stained with the following monoclonal antibodies: anti-
CD45-krome orange (Beckman Coulter (Brea, CA, USA),
cat no. 96416), anti-CD14-PC5.5 (Beckman Coulter, cat no.
A70204), anti-CD19-APC-Alexa Fluor 750 (Beckman
Coulter, cat no. A94681), anti-CD19-APC (BD Pharmingen
(San Jose, CA, USA), cat no. 555415), anti-CD27-PE (BD
Pharmingen, cat no. 555441), anti-CD27-PC7 (Beckman
Coulter, cat no. A54823), anti-CD27-ECD (Beckman
Coulter, customized), anti-IgD-FITC (BD Pharmingen,
cat no. 555778), anti-IgA-FITC (Beckman Coulter, cat
no. 732610), anti-IgG-PECy7 (BD Pharmingen, cat no.
561298) and anti-IgM-APC (BioLegend (San Diego, CA,
USA) cat no. 314510). After staining, cells were analyzed
by 10-color flow cytometer (Navios, Beckman Coulter). B
cells were identified by CD19+ cells gated on CD45 +
CD14- lymphocytes in combination with forward scatter
versus side scatter gating on CD45+ lymphocytes. B cell
subpopulations were identified by using CD27 and IgD
expression gated on B cells. Expression of IgG, IgA and
IgM was analyzed for CD27 + IgD- post-switch and
CD27-IgD- DN B cells, respectively. At least 20,000
CD19+ events were collected for each analysis. The total
number of B cells of various phenotypes was calculated
per microliter of blood, based on the frequency of these
cells among the lymphocytes and the absolute number
of white blood cells.
Single-cell sorting
PBMCs were isolated by Ficoll-Paque Plus separation
(Pharmacia Biotech, Freiburg, Germany) using the stand-
ard protocol. Single B cell sorting from PBMCs was car-
ried out as described previously [28]. Briefly, B cells were
Table 1 Characteristics of patients treated with tocilizumab therapy
Baseline (n = 36) Week 12 (n = 36) Week 24 (n = 36) 1 year (n = 36)
Age, median (range) years 54 (33-79)
% female 77%
Disease duration, median (range) years 9 (2-33)
RF positive 36
ACPA positive 28
RF/ACPA positive 28
mean ± SEM
DAS28 score 5.2 ± 0.3 3.3 ± 0.3ψ 2.7 ± 0.2ψ 1.9 ± 0.2ψ
CRP, mg/dl 0.9 ± 0.1 0.14 ± 0.06ψ 0.09 ± 0.03ψ 0.06 ± 0.02ψ
ESR, mm/hour 32.1 ± 3.4 9.8 ± 1.6ψ 7.2 ± 0.9ψ 5.6 ± 0.8ψ
Patient’s VAS 58.3 ± 4.4 48.6 ± 4.8ψ 34.8 ± 5.4ψ 21.5 ± 4.8ψ
IgA-RF U/ml 122.3 ± 33.3 99.9 ± 26.3ψ 63.3 ± 19.8ψ -
IgA total U/ml 265.4 ± 20.8 237.2 ± 19.5ψ 203.1 ± 18.9ψ -
The primary end point of the study was a reduction in the disease activity score in 28 joints (DAS28) at week 12. Except where indicated otherwise, values are the
mean ± standard error of the mean (SEM). ψP <0.05 versus baseline and Mann-Whitney t test was used for statistics. RF, rheumatoid factor; ACPA, anti-citrullinated
protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analog scale (100 mm); IgA, immunoglobulin A.
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by forward/side scatter; doublets for CD19 positivity were
excluded. DN B cells were defined as CD19 + IgD-CD27-.
Individual DN B cells were sorted in a 96-well plate con-
taining lysis buffer by using FACS ARIA-III cell sorter
(Becton Dickinson, San Jose, CA, USA). Lysis buffer was
comprised of Triton X-100, bovine serum albumin (BSA),
oligo (dT)15 primer, dithiothreitol, RNasin, and RNAse-
free double-distilled H2O or RNAse-free H2O.
cDNA preparation and nested PCR
A mixture comprising RT-PCR buffer, reverse transcript-
ase and nucleotides from Titan One Tube RT-PCR
System (Roche Diagnostics, Mannheim, Germany) was
added into a 96-well plate. cDNA synthesis was carried
out at 50°C for 1 hour. VH3 gene rearrangements com-
prising the largest VH family were amplified by nested
PCRs using family-specific primers as previously described
[29]. Briefly, the cycle program consisted of one cycle at
95°C for 5 min, 50 to 58°C for 1 min, 72°C for 1 min,
followed by 30 cycles of 94°C for 1 min, 50 to 58°C for
30 s, 72°C for 1 min, followed by 5 min incubation at
72°C. Using 5 μl of the PCR product from first amplifi-
cation as template, the second round of nested PCR was
conducted with a primer specific. In order to differenti-
ate different isotypes in DN B cells, CH1μ-, CH1α- and
CH1γ-specific PCRs were carried out using cycle pro-
gram as described previously [30]. The error rate due to
the Taq polymerase used in the amplification process
was estimated to be 1 × 10-4 mutations/bp [31]. VH family-
specific PCR products (350 bp) were separated via electro-
phoresis using 1.5% agarose gel and further purified byusing MinElute Gel Extraction kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Sequencing and analysis
Gel extracted PCR products of Ig-VH3 and isotype-
specific Ig were amplified using BigDye Terminator Cycle
Sequencing Ready Reaction kit followed by sequencing in
genetic analyzer ABI PRISM 310 (Applied Biosystems,
Carlsbad, CA, USA). A total of 2,407 sequences were ana-
lyzed by matching their closest germline counterparts
using the online program JOINSOLVER [32].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software, San Diego, CA, USA) and SPSS
Statistics 22.0 (IBM Corp., Armonk, NY, USA). Values
were always compared with baseline levels by using the
nonparametric Wilcoxon matched pair test and Mann-
Whitney U test. Univariate logistic regression was used to
calculate odd ratios and correlation using Pearson r. The
values ≤0.05 were considered to be significant. ***P <0.0001,
**P <0.001 and *P <0.01.
Results
Double-negative (CD19 + IgD-CD27-) B cells are expanded
in RA
Based on surface expression of IgD and CD27 (Figure 1A),
human peripheral CD19 + B cells were divided into four
subsets: mature naïve B cells (IgD +CD27-), pre-switch
memory B cells (IgD +CD27+), post-switch memory B
cells (IgD-CD27+) and DN B cells (IgD-CD27-). Frequen-
cies of peripheral DN B cells were determined in RA
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and healthy donors (n = 45; median age approximately
52 years). We found significantly enhanced frequencies of
DN B cells in RA patients compared to HD (Figure 1B).
Here, RA patients had a median (range) of 8.4 (2.0 to
18.1) percent of CD19+ DN B cells as compared with 3.3
(1.0 to 7.9) percent in HD. Notably, absolute numbers of
DN B cells of RA with 10.7 (1.9 to 32.9) cells/μl were
comparable to HD with 9.6 (1.7 to 29.5) cells/μl.
DN B cells correlate to clinical response to tocilizumab
During TCZ therapy, DAS28 of all patients declined sig-
nificantly from 5.2 at baseline (BL) to 3.3, 2.7 and 1.9 at
week 12, 24 and 1 year (P <0.0001). The inflammatory
parameters erythrocyte sedimentation rate (ESR) and CRP
were also significantly reduced (Table 1). The clinical re-
sponse was maintained up to 1 year and there were no
serious adverse events or infections during the study. At
week 12, during IL-6 inhibition with TCZ therapy 14 out
of 36 patients reached a EULAR good response, 20 pa-
tients reached a moderate response and 2 patients were
non-responders. Interestingly, we found that good EULAR
responders to TCZ at week 12 had a significantly lower
frequency of DN B cells compared to moderate re-
sponders, at BL. The same correlation was also found
for absolute numbers of DN B cells at BL (Figure 1C-D).
There was no significant correlation between frequency
of DN B cells with DAS28 (R = -0.007; P = 0.97) and
CRP levels (R = 0.07; P = 0.70). Univariate logistic re-
gression analysis revealed that the frequency of DN B
cells at BL is inversely correlated with a subsequent
EULAR good response with a significant (P = 0.024) odds
ratio of 1.48 (95% confidence interval (CI) as 1.05 to 2.06)
favoring EULAR good response. This indicates that the
percentage of DN B cells is elevated in RA and correlated
with EULAR response to TCZ.
Phenotypic isotype distribution of CD27-IgD- DN and
post-switch B cells in RA and their modulation during
IL-6R inhibition
In order to reveal the isotypic distribution of DN B cells,
we measured the surface expression of IgG, IgA and
IgM isotypes and followed them in RA patients (n = 36)
during TCZ treatment till week 24. DN B cells showed a
heterogeneous mixture of cells containing IgG+, IgA+
and IgM+ expressing B cells with a dominance of IgG
isotype. In detail, DN B cells contained a median (range)
of 60.6% (40.9 to 86.7) IgG+ isotype of total DN B cells,
24.7% (10.0 to 64.2) of IgA+, and 8.0% (2.3 to 25.8) of
IgM+ B cells. For comparison, post-switch memory B
cells displayed an almost equal distribution of IgG+ and
IgA+ cells; 45.3% (26.2 to 67.3) IgG+ and 42.7% (24.5 to
57.4) IgA+ (Figure 2). The distribution of IgG+, IgA+
and IgM+ DN B cells in HD were comparable to RApatients (Additional file 1). Since IL-6 inhibition has
been shown to influence B cell maturation, we studied
DN B cells during TCZ therapy. TCZ did not change the
elevated frequency of the overall population of CD27-
IgD- DN B cells. However, by analyzing the Ig isotypes
in CD27-IgD- DN B cells we found a significant relative
decrease of IgA+ DN cells from 24.7% (10.0 to 64.2) me-
dian (range) to 18.4% (4.8 to 34.7) at week 12 (P = 0.004)
and 20.5% (4.6 to 33.8) at week 24 (P = 0.04), respect-
ively. We did not find any remarkable changes in IgG+
or IgM+ B cells (Figure 2B). Moreover IgA+ DN B cells
declined also significantly in absolute numbers (P <0.05)
Additional file 2A). In contrast, the frequency of both
IgA+ and IgG+ in the post-switch B cells compartment
was not influenced during TCZ therapy (Figure 2C), indi-
cating a more dynamic IgA response in the DN compart-
ment. Interestingly serum IgA levels as well as RF-IgA
both declined significantly during TCZ therapy (Table 1).
Somatically mutated Ig-receptors of DN B cells and their
modulation during IL-6R
In a subsequent study we performed molecular analysis of
DN B cells and analyzed in detail the Ig-R of individually
sorted cells from HDs (n = 3) and from RA patients during
TCZ (n = 9) or anti-TNF-α therapy (n = 4). As shown pre-
viously, [33] Ig-VH3 gene rearrangements of DN B cells
Ig-R showed less mutation compared to pre-switch and
post-switch B cells. Specifically, mutational frequency of
DN B cells was 4.0 ± 0.2% compared to 4.5 ± 0.2% for
pre-switch B cells and 6.2 ± 0.3% for post-switch B cells.
Moreover, the mutational frequency of DN B cells was
comparable in RA and HD (Additional file 2A).
During TCZ therapy however, the mutational fre-
quency of Ig-R of DN B cells was significantly reduced
at week 12, week 24 and 1 year (Figure 3A). The muta-
tional frequency of DN B cells decreased from 4.04 ±
0.2% (BL) to 2.52 ± 0.2% at week 12 (P <0.0001), 1.98 ±
0.3% at week 24 (P <0.0001) and 1.89 ± 0.3% (P <0.0001)
at 1 year respectively during TCZ (Figure 3A). Consist-
ent with that, highly mutated sequences (>20 mutations
per sequence) decreased from 46.2 ± 5.1% (BL) to 28.7 ±
5.5% at week 12 (P = 0.018), 23.1 ± 6.8% at week 24 (P =
0.035) and 17.3 ± 3.9% at 1 year (P = 0.0003) during TCZ
therapy. In parallel, a significant increase of unmutated
(0 mutation per sequence) sequences from 15.1 ± 3.4%
(BL) to 22.7 ± 3.7% at week 12 (P = 0.05), 32.1 ± 4.6% at
week 24 (P = 0.005) and 37.1 ± 4.6% at 1 year (P = 0.004)
was found (data not shown). In order to evaluate TCZ-
specific influences on Ig gene rearrangements, we also
studied patients (n = 4) who underwent TNF-α inhib-
ition using adalimumab therapy (Figure 3B). Mutational
frequency of Ig-R did not change in DN B cells during
adalimumab therapy (Figure 3B). Both therapeutic anti-
cytokine interventions significantly reduced clinical
Figure 2 Surface expression of immunoglobulin isotypes during IL-6R inhibition. (A) Representative FACS plots showing the expression of
immunoglobulin isotypes, IgA, IgG and IgM on gated DN and post-switch B cells. (B) During IL-6R inhibition, IgA+ DN B cells decreased significantly
from 24.7 (10.0 to 64.2) percent median (range) to 18.4 (4.8 to 34.7) at week 12 (P = 0.004) and 20.5 (4.6 to 33.8) at week 24 (P = 0.04) respectively. There
were no remarkable changes in relative IgG+ and IgM+ DN B Cells. (C) IgA+ and IgG+ post-switch B cells were not influenced during IL-6R inhibition.
BL, baseline, W12, week 12 and W24, week 24. DN, double-negative; Ig, immunoglobulin; IL-6R, interleukin-6 receptor.
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of 5.2 at baseline to 3.3 at week 12, 2.7 at week 24 and
1.9 at 1 year. During anti-TNF-α therapy DAS28 de-
clined from a mean of 4.7 at BL to 3.1 at week 12, 2.7 at
week 24 and 1.6 at 1 year. These results indicate that
anti-TNF-α therapy does not influence the process of
somatic hypermutation of DN B cells as is observed
during IL-6R inhibition.
Ig-specific isotypes are modulated during IL-6R inhibition
Since DN B cells are a heterogeneous population of IgG,
IgA and IgM isotypes, we addressed if the TCZ therapy
has distinct influences on different isotypes. We per-
formed isotype-specific PCRs from single-sorted DN B
cells, and amplified the CH1μ-, CH1γ- and CH1α-specific
immunoglobulin gene rearrangements (Figure 3C). At
baseline, the isotype-specific Ig-R analysis revealed a
significantly higher mutational frequency of IgA+ DN B
cells (P = 0.01) compared to IgG+ DN B cells at BL. As
expected IgM+ DN B cells showed the lowest muta-
tional frequency. However during TCZ therapy, all three
isotypes (IgA+, IgG+ and IgM+) of DN B cells showed a
significantly reduced mutational frequency. Mutational
frequency of IgA+ cells were found to be reduced (mean ±
standard error of the mean (SEM)) from 5.42 ± 0.30% (BL)
to 3.35 ± 0.22% at week 12 (P <0.0001), 2.41 ± 0.34% at
week 24 (P <0.0001) and 2.26 ± 0.33% (P <0.0001) at 1 year,respectively. The mutational frequency of IgG+ cells re-
duced from 4.45 ± 0.20% (BL) to 2.51 ± 0.22% at week 12
(P <0.0001), to 2.16 ± 0.23% at week 24 (P <0.0001) and
2.00 ± 0.20% (P <0.0001) at 1 year, respectively. Simi-
larly, the mutational frequency of IgM+ cells also de-
creased from 2.87 ± 0.32% (BL) to 1.55 ± 0.23% at week
12 (P = 0.0016), 0.98 ± 0.21% at week 24 (P = 0.0008)
and 0.67 ± 0.17% (P <0.0001) during 1-year TCZ treat-
ment (Figure 3C). These data are consistent with the
overall VH3 analysis of individual DN B cells during
TCZ treatment (Figure 3A).
CDR3 length and targeting of mutational hotspots motifs
during IL-6R inhibition
Along with SHM, the length of the third complementary
determining region (CDR3) is considered a signature of
antigen contact and T cell help, and it represents im-
prints of selection. CDR3 lengths of VH gene rearrange-
ments at different time points are shown in Figure 4A.
We showed that CDR3 length of DN B cells increased
from median (range) 45.0 (16.0 to 81.0) base pair (bp)
(BL) to 48.0 (18.0 to 85.0) bp at week 12 (P = 0.0004),
48.0 (18.0 to 85.0) bp at week 24 (P <0.0001) and 50
(21.0 to 91.0) bp (P <0.0001) at 1 year during TCZ ther-
apy (Figure 4A). Analysis of the frequency of targeted
RGYW/WRCY mutations (R, purine; Y, pyrimidine; W,
A/T) showed that it decreased significantly from median
Figure 3 Ig-receptor somatic hypermutation of gene rearrangements during IL-6R and TNF-α inhibition in DN B cells. (A) Ig-VH3 gene
rearrangements during IL-6R inhibition. Reduction in mutational frequency of Ig-VH3 gene rearrangements of DN B cells from the peripheral blood
of RA patients during TCZ therapy. The mutational frequency was significantly reduced at week 12, 24 and 1 year (***P <0.0001 compared to BL).
(B) Ig-receptor somatic hypermutation of VH3 gene rearrangements during TNF-α inhibition. During TNF-α inhibition by adalimumab, a comparable
mutational frequency of VH gene rearrangements of DN B cells from the peripheral blood of RA patients were observed at all time points.
(C) Ig-receptor somatic hypermutation of isotype-specific IgA+, IgG+ and IgM+ gene rearrangements during IL-6R inhibition in DN B cells. At
the BL, the mutational frequency of IgA+ DN B cells is significantly higher compared to IgG+ and IgM+ DN B cells. During TCZ therapy, all isotypes
IgA+, IgG+ and IgM+ DN B cells showed a significantly reduced mutational frequency (***P <0.0001,**P <0.001). In a scatter plot, the line represents
mean of all values and each dot depicts the mutational frequency of a single sequence. P values were determined by Wilcoxon test using GraphPad
Prism 5. (BL, baseline; W12, week 12; W24, week 24; n, number of individuals; s, number of sequence analyzed). DN, double-negative; HD, healthy
donor; Ig, immunoglobulin; IL-6R, interleukin-6 receptor; RA, rheumatoid arthritis; TCZ, tocilizumab; TNF-α, tumor necrosis factor alpha.
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26.1) at week 12 (P = 0.046), 20.7 (14.9 to 23.4) at week 24
(P = 0.004) and 19.2 (12.6 to 24.5) at 1 year (P = 0.004)
during TCZ therapy (Figure 5A). Frequency analysis of
mutational hotspot targeting and CDR3 length analysis
during anti-TNF-α therapy also revealed no changes in
DN B cells Ig-receptor (Figures 4B and 5B). Furthermore,
the frequency analysis of targeted mutations revealed that
there was a significant decrease of this targeted mutations
from baseline to week 12, 24 and 1 year in all isotype-
specific IgA+, IgG+ and IgM+ DN B cells during TCZ
therapy (Figure 5C). Likewise, CDR3 length of isotype-
specific DN B cells increased from BL to week 12, week
24 and 1 year during TCZ therapy (Figure 4C). Overall,
these findings indicate that TCZ therapy not only modu-
lates acquired SHMs in Ig-R of DN B cells, but also exerts
effects on the length of CDR3.
Discussion
With increased understanding of mechanistic pathways
of B cell involvement in autoimmune diseases, a numberof studies have provided evidence that B cells play a
central role in the pathogenesis of RA and that certain
subsets may be exploitable as biomarkers. Memory B
cells, in particular, seem to be important in driving
chronic inflammation [28,34]. Targeting pre-switch and
post-switch memory B cells has been found to be im-
portant for the response to rituximab [35]. However the
impact of different memory B cell subsets has not been
thoroughly studied. We recently showed that in vivo IL-
6R inhibition by TCZ does influence the peripheral pre-
switch and post-switch memory B cells in RA [14,25].
Because CD27-IgD- DN B cells also carry features of
memory B cells [19,20], we were particularly interested
in studying their behavior in active RA, since there is
scant literature available for RA. DN B cells confer a
notable component of the peripheral blood B cell com-
partment in RA patients (Figure 1A). Similar to others
[35,36], we found a relatively higher frequency of the
DN B cell subset in RA patients compared to healthy
donors, whereas the absolute numbers of DN B cells
were comparable to HD is mainly due to lymphopenia
Figure 4 CDR3 length during IL-6R and TNF-α inhibition. (A) Significant increase in the CDR3 length of Ig-VH gene rearrangements of DN B
cells from the peripheral blood of RA patients during IL-6R inhibition. (***P <0.0001). (B) During TNF-α inhibition, a comparable CDR3 length of
Ig-VH gene rearrangements of DN B cells were observed at all time points. (C) There is significant increase in the length of the CDR3 in all three
isotypes specific to DN B cells during IL-6R inhibition. P values were determined by Wilcoxon test using GraphPad Prism 5. CDR3, the length of
the third complementary determining region; DN, double negative; IL-6R, interleukin-6 receptor; RA, rheumatoid arthritis; TNF-α, tumor necrosis
factor alpha.
Figure 5 Frequency of targeted mutations within hotspot motifs during IL-6R and TNF-α inhibition. (A) A significant reduction in frequency of
targeted mutations within RGWY/WRCY is found in Ig-VH gene rearrangements of DN B cells during TCZ therapy (
*P = 0.046, **P = 0.004). (B) During
TNF-α inhibition, a comparable mutational hotspot targeting of VH gene rearrangements of DN B cells were observed at all time points. (C) A
significant reduction in frequency of targeted mutations within RGWY/WRCY is found in all three isotypes specific to DN B cells during IL-6R
inhibition. P values were determined by Wilcoxon test using GraphPad Prism 5. DN, double negative; Ig, immunoglobulin; IL-6R, interleukin-6
receptor; TCZ, tocilizumab; TNF-α, tumor necrosis factor alpha.
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described to be related to aging, persistent antigen stimu-
lation and seem to reflect overall B-cell hyperactivity
[19,23,37-39]. In our study, elevation of DN B cells did
not reflect simply inflammation since their number did
not correlate to CRP or DAS28 levels.
We describe a heterogeneous DN B cell population
containing IgG+, IgA+ and IgM+ DN B cells with pre-
dominance of the IgG clearly different from post-switch
memory B cells (Figure 2A). During TCZ therapy, there
was moderate influence on the phenotypic composition
of the DN compartment. Nevertheless, the IgA-DN B
cell phenotype seems to be particularly amenable to IL-
6R inhibition - the percentage of IgA+ DN B cells sig-
nificantly decreased during TCZ therapy (Figure 2B).
Also absolute numbers of IgA+ DN cells were reduced
significantly (Additional file 3). Moreover we see a sig-
nificant reduction of serum IgA (Table 1 and reference
[14]) as well as RF-IgA levels (Table 1). This highlights
the IL-6 susceptibility of the IgA isotype. However, it
should be pointed out that our data provides no direct
relation of IgA-DN B cells to declining IgA serum fac-
tors. Nevertheless IL-6 has been ascribed a critical player
in the development of local IgA antibody responses and
a remarkable reduction of mucosal IgA-producing cells
has been reported in mice with targeted disruption of the
gene that encodes IL-6 [40]. Future experiments need to
address how peripheral IgA+ DN B cells may be related to
the mucosal immune system.
SHM of immunoglobulin gene rearrangements is a hall-
mark of B cell maturation into memory cells after antigen
encounter. Despite their mainly switched phenotype, we
also found the mutational frequency of DN B cells in RA
to be significantly lower compared to post-switch B cells
and similar to pre-switch B cells. This has been previously
reported for other diseases and older people [19,20,24,25].
We found a significant decrease in mutational frequency
of the B cell receptor (BCR) at week 12, 24 and over a year
during TCZ therapy (Figure 3A). TCZ treatment again in-
duces profound changes with reduced mutational status
in all three isotypes (Figure 3C). Interestingly, IgA+ DN B
cells also harbored the highest mutational frequency com-
pared to IgG+ and IgM+ DN B cells, which was evident in
RA as well as healthy donors (Additional file 2B).
It is known that SHM favors defined mutational hot-
spots. In particular, RGYW/WRCY motif mutations are
preferentially targeted by T cell-dependent signals includ-
ing CD40-CD40 ligand interactions [41]. The decrease in
frequency of targeted mutations within RGYW/WRCY
and increase in CDR3 during IL-6R inhibition indicates
that during therapy the DN B cell population consists of
less antigen-experienced B cells. This effect seems mainly
influenced by IL-6R inhibition therapy since we did not
observe any change in these parameters during anti-TNF-α therapy using adalimumab (Figure 3B), although both
biologics resulted in good reduction of clinical inflamma-
tion. In a previous study looking at the pre-switch B cell
compartment, we observed a similar pattern with adali-
mumab failing to influence Ig-R mutation [25]. Therefore,
it seems likely that IL-6R blockade does affect B cell mat-
uration in vivo to a substantial extent. However, at the
moment it is not clear how direct and indirect effects on
B cells contribute to the observed effects since TCZ is
also reported to reduce activated CD4+ T cells as early
as 12 weeks after treatment [42]. Data still leaves these
questions open. DN B cells are hypothesized to resem-
ble transient effector B cells [43]. A recent report sug-
gested that Syk++ B cells lacking CD27 expression
represent a unique atypical memory-like B cell, which
may be relevant for IgG+ plasmablast generation [44].
Furthermore they might derive from incomplete GC or
alternatively from extrafollicular reactions [43]. Since
mutational frequencies of DN and pre-switch B cells are
significantly lower than typical post-switch B cells, it
might be suggested that either of these cells are pre-
germinal centre or leave the GCs quickly by shedding
CD27. On the other hand, DN B cells still could fail to
upregulate CD27 expression before leaving GCs since
CD27-negative memory B cells have also been found
and isolated from human tonsils [45]. Since shedding or
downregulation of CD27 have been reported as an indica-
tion of continuous antigen stimulation and T cell exhaus-
tion, our observed connection of DN B cells numbers to
response to IL-6R inhibition may reflect a state of chronic
B cell hyperactivity closely linked to IL-6 [37-39].
Furthermore, the data are consistent with the idea that
DN memory B cells are distinctly generated or have a
shorter half-life than conventional post-switch memory
B cells resulting in a measurable impact of IL-6R block-
ade on DN B cells.
The search for predictive biomarkers to individualize
treatment strategies in RA is of current interest. For IL-
6R inhibition with TCZ, predictive markers for response
have not yet been identified. In our study, we were able
to relate the level of peripheral DN B cells to the clinical
response to TCZ (Figure 1B-C). Patients achieving EULAR
good response at week 12 had significantly lower percent-
ages and absolute numbers of DN B cells at baseline before
TCZ therapy. In univariate logistic regression analysis, a
lower frequency of DN B cells showed an odds ratio of
1.48 for achieving a EULAR good response to TCZ. It is
important to note that the frequency of DN B cells is
not correlated to CRP or DAS28 levels at baseline. Thus
CD27-IgD- DN B cells may indicate an elevated B cell
activity in RA that is not reflected by these inflamma-
tory markers but is susceptible to TCZ. This may allow
future studies to exploit DN B cells as biomarkers for
response to TCZ.
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In summary, we demonstrate a significantly higher popu-
lation of CD27-IgD- DN B cells in RA patients. These DN
B cells are a mixture of somatically mutated IgG, IgA and
IgM isotype-bearing cells with a dominance of IgG iso-
type. TCZ therapy results in a decrease in the frequency
of IgA+ DN B cells in particular. In parallel, a decrease
of serum IgA and RF-IgA levels is observed. On the mo-
lecular level, TCZ therapy reduces the mutational fre-
quency and RGYW hotspot targeting in all DN B cells
over a period of 1 year. Based on these current findings,
DN memory B cells may serve as a candidate biomarker
for response to TCZ therapy as lower baseline values of
these cells were related to higher proportions of EULAR
good responders.
Additional files
Additional file 1: Surface expression of DN B cells immunoglobulin
isotypes in HD and RA patients. (A) The distribution of IgA+, IgG+
and IgM+ DN B cells were comparable in HD and RA patients before
undergoing therapy. (B) Similarly in post-switch memory B cells,
distributions of IgA+ and IgG+ cells were comparable.
Additional file 2: Ig-receptor somatic hypermutation of VH3 and
isotype-specific IgA+, IgG+ and IgM+ gene rearrangements of DN B
cells in HD and RA. (A) Comparable mutational frequency of VH3 gene
rearrangements of DN B cells from the peripheral blood of RA patients
before undergoing therapy and HD. (B) Isotype specific IgA+, IgG+ and
IgM+ gene rearrangements of DN B cells were comparable.
Additional file 3: Surface expression of immunoglobulin isotypes
during IL-6R inhibition (absolute cell numbers). (A) IgA+ DN B cell
absolute numbers per μl are decreased significantly from median (range)
1.9 (0.42 to 9.5) to 1.4 (0.4 to 6.0) at week 24 (P = 0.04). Absolute cell
numbers of IgG+ and IgM+ DN B cells are showing a trend for reduced
numbers during TCZ therapy. (B) Absolute cell numbers of isotype
specific IgG+ and IgA+ post-switch B cells shows a weak trend to
reduced numbers during TCZ therapy. Total number of patients = 36.
BL = baseline, W12 = week 12 and W24 = week 24. P values were
determined by Mann-Whitney U test using GraphPad Prism 5. (***P <0.0001,
**P <0.001 and *P <0.05).
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